AVXL · Anavex Life Sciences Corp.
$3.22
-0.05 (-1.53%)
At close · Aug 14
Market Cap
$298.40M
Shares
92.67M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.22
Open$3.25
Day$3.14–3.27
52W close$2.34–10.26
Avg vol 30d971K
Short int14.4M · 15.6% float · 14.4d
Short vol38%
Last earningsFeb 9, 2026
DataJan 2020–Aug 2026
Filing10-Q · Feb 9
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Feb 9, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
+19%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
11%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+35%
trailing
6-month return
−23%
trailing
YTD return
−10%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +24 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.57% of float · ▲ +2.0% MoM · 14.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
177 holders — mid 3-yr range
Squeeze score
81
high risk · 0–100
Fundamentals
EPS growth
−4%
Y/Y
Free cash flow
$-39.0M
Balance sheet
$102.6M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
+19%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
11%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +24 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.57% of float · ▲ +2.0% MoM · 14.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
177 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 11%
Range high $10
vs 200-day avg -15%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVXL
this stock
Anavex Life Sciences Corp.
|
$298.40M | -9.6% | — | — | 15.6% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVXL | -3.6% | +34.7% | -22.6% | +17.1% | -9.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.0% | +30.3% | -36.4% | +13.2% | -23.4% |